In new-onset plaque psoriasis treated early with secukinumab, 20.8% sustained PASI 90 at week 104, a year after stopping treatment (key secondary endpoint); 44% (29/66) entering treatment-free follow-up did not relapse. Open label.
RCTn = 77
Iversen et al. Impact of early treatment of psoriasis on disease recurrence-Results from the STEPIn study